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OBJECTIVES The aims of this study were to determine whether chronic or acute impairment of flow
mediated vasodilation (FMD) in the brachial artery of smokers can be restored or preserved
by the antioxidant vitamin E.
BACKGROUND Transient impairment of endothelial function after heavy cigarette smoking and chronic
endothelial dysfunction in smokers result at least in part from increased oxidative stress.
METHODS We studied 22 healthy male smokers (mean 6 SD, 23 6 9 cigarettes per day) randomly
assigned to receive either 600 IU vitamin E per day (n 5 11, age 28 6 6 years) or placebo
(n 5 11, age 27 6 6 years) for four weeks and 11 age-matched healthy male nonsmokers.
Flow mediated vasodilation and endothelium-independent, nitroglycerin-induced dilation
were assessed in the brachial artery using high resolution ultrasound (7.5 MHz) at baseline
and after therapy. Subjects stopped smoking 2 h before the ultrasound examinations. At the
end of the treatment period, a third scan was obtained 20 min after smoking a cigarette
(0.6 mg nicotine, 7 mg tare) to estimate transient impairment of FMD.
RESULTS Flow mediated vasodilation at baseline was abnormal in the vitamin E (5.3 6 3.8, p , 0.01)
and in the placebo group (6.4 6 3.5, p , 0.05) compared with nonsmoking controls (11.6 6
4.7). Using a two-way repeated measures analysis of variance (ANOVA) to examine the
effects of vitamin E on FMD, we found no effect for the grouping factor (p 5 0.5834) in the
ANOVA over time but a highly significant difference with respect to time (p 5 0.0065). The
interaction of the time factor and the grouping factor also proved to be significant (p 5
0.0318). Flow mediated vasodilation values remained similar after treatment for four weeks
in both groups but declined faster after smoking a cigarette in subjects taking placebo
compared with those receiving vitamin E (p values from successive differences for the
time/group factor: 0.0001/0.0017). The transient attenuation of FMD (calculated as the
percent change in FMD) was related to the improvement of the antioxidant status, estimated
as percent changes in thiobarbituric acid-reactive substances (r 5 20.67, p 5 0.0024).
Nitroglycerin-induced dilation did not differ between study groups at baseline or after
therapy.
CONCLUSIONS These results demonstrate that oral supplementation of vitamin E can attenuate transient
impairment of endothelial function after heavy smoking due to an improvement of the
oxidative status but cannot restore chronic endothelial dysfunction within four weeks in
healthy male smokers. (J Am Coll Cardiol 2000;35:277–83) © 2000 by the American
College of Cardiology
Endothelial dysfunction occurs at an early stage of athero-
sclerosis and has been observed in coronary and peripheral
arteries of long-term smokers (1,2) as well as after heavy
cigarette smoking (3,4). The precise mechanism of
smoking-related endothelial dysfunction is not well under-
stood and very likely multifactorial. However, recent clinical
and experimental observations strongly suggest a role of
oxygen-derived free radicals (5–7). Cigarette smoke con-
tains large amounts of free radicals, which may degrade
nitric oxide released from the endothelium and also
produce highly reactive intermediates, resulting in endo-
thelial injury.
Epidemiologic studies have found an inverse association
between the frequency of coronary artery disease (CAD)
and dietary intake of antioxidant vitamins (8,9). However, a
possible cause and effect relation between the intake of
antioxidants and a reduction in the complications of CAD
has thus far only been shown for vitamin E (10).
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With regard to the effects of antioxidant vitamins on
endothelial function, controversial results have been ob-
tained. Improvement of endothelial dysfunction in smokers
was noticed in the forearm vasculature after intraarterial
infusion of the watersoluble antioxidant vitamin C (11) and
in the brachial artery after intravenous vitamin C infusion
(12). The beneficial effect of vitamin C supplementation
was associated with a decrease in thiobarbituric acid–
reactive substances (TBARS) as an index of oxidative stress.
In contrast, oral application of vitamin C for one month
showed no beneficial effect on endothelial function in the
forearm vessels of patients with hypercholesterolemia (13)
but resulted in acute improvement of endothelium-
dependent vasodilation in the brachial artery of patients
with CAD when applied at a higher dose (14).
Recently, we demonstrated that the oral intake of vitamin
E, one of the main lipid-soluble antioxidants in human
plasma lipoproteins, in addition to lipid lowering therapy,
restored vascular reactivity in the brachial artery of hyper-
cholesterolemic men (15). In contrast, vitamin E alone
failed to improve endothelial function in forearm circulation
of patients with hypercholesterolemia (13). However, the
effect of vitamin E supplementation on endothelial function
in the brachial artery of smokers is unknown.
In this study, we hypothesized that vitamin E supple-
mentation, through an antioxidant effect, may restore
chronic or preserve acute impairment of endothelium-
dependent vasodilation in the brachial artery.
METHODS
Subjects and treatment. In a randomized, double-blind,
placebo-controlled trial, we studied 22 young, healthy male
smokers (mean 6 SD, 23 6 9 cigarettes per day) randomly
assigned to receive either all-racemic alpha-tocopherol
(Roche Austria, Vienna), the most active form of vitamin E,
at a dosage of 600 IU (n 5 11, age 28 6 6 years) or placebo
(n 5 11, age 27 6 6 years) for four weeks. Both substances
were encapsuled without any visible difference and the
ultrasound operator was blinded to the group assignment.
The reliability of medication intake was controlled by taking
pill counts, which revealed no essential irregularities. Two
probands, one in each group, did not complete the study
(withdrawal of consent). Thus, 22 smokers (11 probands in
each group) could be statistically analyzed after conclusion
of the study. Both study groups were compared with an
age-matched control group of 11 male nonsmokers to
demonstrate that flow-mediated dilation (FMD) at baseline
was abnormal among the smokers. No participant had a
history of hypercholesterolemia, hypertension or diabetes
mellitus. None of the participants took antioxidative drugs
before this study. The investigation conformed with the
principles outlined in the Declaration of Helsinki. Written,
informed consent was obtained from all participants.
Assessment of vasodilation and blood flow. Endothelium-
dependent FMD following reactive hyperemia and
endothelium-independent nitroglycerin-induced dilation
(NMD) were examined in the brachial artery according to
the method described by Celermajer et al. (16). Using high
resolution ultrasound (7.5 MHz linear array transducer),
measurements of the right brachial artery were taken at rest
after lying quietly for at least 10 min, after cuff deflation
completing suprasystolic compression (250 mm Hg for
4.5 min) of the right upper arm and after sublingual
application of 0.8 mg nitroglycerin. Scans of the brachial
artery were taken proximal to the bifurcation of the radial
and the ulnar artery above the antecubital fossa at end
diastole, incident with the R wave on a continuously
recorded electrogram by the same ultrasound operator.
Diameter measurements were taken from one media-
adventitia interface to the other for at least three times at
baseline and every 30 s following reactive hyperemia and
after administration of nitroglycerin. The maximum FMD
and NMD diameters were calculated as the average of the
three consecutive maximum diameter measurements follow-
ing hyperemia and nitroglycerin, respectively. Vasodilation
was then calculated as the percent change in diameter
compared with baseline. The impairment of FMD after
heavy smoking (delta FMD) was estimated as the percent
change in FMD values compared with baseline.
In all subjects, blood flow was calculated at rest and
within 15 s after cuff deflation by multiplying the velocity
time integral of the flow signal by the heart rate and the
vessel cross-sectional area (3.14 3 D2/4). Reactive hyper-
emia was then calculated as percent change in blood flow
during reactive hyperemia compared with baseline.
Ultrasound measurements were performed at baseline
and after therapy for four weeks. Subjects stopped smoking
2 h before the examinations. At the end of the treatment
period, a third scan was obtained 20 min after smoking a
cigarette (0.6 mg nicotine, 7 mg tare) to estimate transient
impairment of FMD.
The mean range of intraobserver difference for measure-
ments of baseline diameter was 0.10 6 0.07%, that of
%FMD 2.4 6 2.2% and that of %NMD 2.7 6 1.9% as
reported elsewhere (17).
Determination of lipids and lipoproteins. Cholesterol
and triglycerides were measured enzymatically using assay
kits from Boehringer Mannheim (Mannheim, Germany).
High-density lipoprotein cholesterol was measured from the
Abbreviations and Acronyms
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supernatant after precipitation with polyethylene glycol
(Reagent A from Immuno A.G., Vienna, Austria). Low-
density lipoprotein cholesterol (LDL-C) was calculated
according to the Friedewald equation.
Alpha-tocopherol measurements in human plasma sam-
ples. The neutral lipid fraction (200 ml) including alpha-
tocopherol, the most active form of vitamin E, was extracted
in a basic extraction system consisting of 200 ml ethanol,
200 ml H2O and 200 ml hexane. The upper organic layer (20
ml) containing alpha-tocopherol was analyzed by high-
performance liquid chromatography using an ExSil 100
20 3 0.46 cm silica column (mobile phase: hexane/1%
ethanol, 1 ml/min) and fluorescence detection (Hitachi, E:
295 nm/Em: 390 nm) (18). Quantitation was performed by
peak area comparison with external alpha-tocopherol stan-
dards of known concentrations. The alpha-tocopherol se-
rum level was then normalized to LDL-C because there is
evidence in the literature that the vitamin E content in
LDL-C and not in the whole plasma correlates with lipid
peroxidation (19,20). The increase of alpha-tocopherol/
LDL-C (delta alpha-tocopherol/LDL-C) under therapy
was calculated as the percent change in alpha-tocopherol/
LDL-C.
Determination of malondialdehyde with thiobarbituric
acid. The measurements of TBARS are based on the
reaction of malondialdehyde, a secondary breakdown prod-
uct of lipid hydroperoxides, with thiobarbituric acid (TBA).
The assay was performed as described previously (21). The
plasma sample was mixed with two volumes of cold 10%
trichloroacetic acid for protein precipitation. Following
centrifugation, the supernatant was mixed with an equal
volume of 0.67% TBA in a boiling water bath for 10 min.
After cooling, the absorbency was measured at 532 nm, and
concentration of malondialdehyde was calculated from ep-
silon 5 153 000 M21 cm21 (21). Measurements were
performed in duplicate. The decrease of TBARS (delta
TBARS) under therapy was calculated as the percent
change in plasma TBARS levels.
Statistical analysis. Results are expressed as mean 6 stan-
dard deviation (SD). Differences between groups were
analyzed using one factor analysis of variance (ANOVA)
followed by Scheffe’s test, when comparing all three study
groups (including nonsmoking controls) and Student t test,
when comparing the vitamin E with the placebo group only.
To examine whether FMD can be restored or preserved by
vitamin E, a two-way repeated measures ANOVA with the
group factor vitamin E/placebo and the repeated factor time
(three levels: baseline/after four weeks/after heavy cigarette
smoking) was performed. Successive differences contrasts
between neighboring points in time were calculated as
supportive statistical analyses. Univariate analyses of the
effects of delta alpha-tocopherol/LDL and delta TBARS on
delta FMD as well as of cigarettes smoked per day on
TBARS levels were performed with linear regression. Dif-
ferences were considered significant at p , 0.05.
RESULTS
Clinical and biochemical parameters. No differences were
found among all three study groups with regard to age,
lipids and lipoproteins serum levels (Table 1). Alpha-
tocopherol and TBARS plasma levels at baseline were
similar in the placebo and the vitamin E group. Vitamin E
supplementation for four weeks led to significant increases
of alpha-tocopherol serum levels and alpha-tocopherol se-
rum levels normalized to LDL-C as well as of delta
alpha-tocopherol and delta alpha-tocopherol/LDL. The
percent changes of TBARS under therapy were also differ-
ent between study groups (Table 2).
Vasodilation and blood flow responses. Baseline diameter
and increases in blood flow during reactive hyperemia were
similar among the study groups at baseline (Table 1) and
after treatment for four weeks, respectively. Thus, it can be
assumed that the stimulus for endothelium dependent
vasodilation was similar in all study groups and that it was
not influenced by the study medication. Smoking a cigarette
did not effect brachial artery diameter and blood flow.
Comparing the two study groups consisting of male
Table 1. Characteristics of the Study Groups
Placebo (n 5 11) Vitamin E (n 5 11) Controls (n 5 11)
Age (yr) 27 6 6 (19–36) 28 6 6 (22–34) 28 6 5 (19–36)
Cigarettes per day 21 6 4 (15–30) 24 6 13 (5–40) —
Pack-years 15.2 6 11.6 (1.5–31.5) 11.8 6 9.1 (1.5–38) —
Triglyceride (mg/dL) 139 6 94 (53–383) 147 6 94 (70–323) 131 6 64 (54–270)
Cholesterol (mg/dL) 191 6 40 (111–242) 211 6 24 (167–257) 188 6 27 (161–243)
HDL-C (mg/dL) 39 6 2 (26–50) 40 6 3 (25–52) 48 6 15 (26–75)
LDL-C (mg/dL) 124 6 32 (62–173) 147 6 28 (106–194) 121 6 27 (88–163)
Baseline diameter (mm) 4.7 6 0.9 (3.9–5.6) 4.9 6 0.4 (4.5–5.8) 4.6 6 0.7 (3.8–5.5)
Hyperemia (%) 334 6 165 (175–674) 386 6 147 (160–496) 359 6 180 (154–577)
Controls 5 nonsmokers; HDL-C 5 high-density lipoprotein cholesterol; LDL-C 5 low-density lipoprotein cholesterol; placebo 5 smokers receiving placebo; vitamin E 5
smokers receiving vitamin E.
Values are mean 6 SD (range). No comparisons were significantly different.
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smokers with an age-matched control group of male non-
smokers, FMD was impaired in both the vitamin E (5.3 6
3.8 vs. 11.6 6 4.7, p , 0.01) and the placebo groups (6.4 6
3.5 vs. 11.6 6 4.7, p , 0.05).
By performing a two-way repeated measures ANOVA,
we found no effect for the grouping factor (group factor p
value 5 0.5834) in the ANOVA over time. With respect to
time, there was a highly significant difference (time factor p
value 5 0.0065), and the interaction of the time factor and
the grouping factor also proved to be significant (p 5
0.0318), thus confirming the beneficial effect of vitamin E
supplementation (Fig. 1).
Supporting statistical analyses revealed a stronger decline
of FMD values after acute cigarette smoking in subjects
taking placebo compared with those receiving vitamin E (p
values from successive differences for the time/group factor:
0.0001/0.0017) (Fig. 2). However, FMD values did not
change, neither after vitamin E nor after placebo intake for
four weeks, when subjects stopped smoking at least 2 h
before the ultrasound examination (p values from successive
differences for the time/group factor: 0.3099/0.5756).
Nitroglycerin-induced vasodilation was similar in all
study groups at baseline and after the treatment period.
Relationship between oxidative stress, smoking habits
and FMD. Univariate analyses over both study groups
revealed significant inverse correlations between the tran-
sient impairment of FMD after acute smoking (delta FMD)
and the improvement of the antioxidant status (delta
TBARS, r 5 20.67, p 5 0.0024; delta alpha-tocopherol/
LDL, r 5 0.51, p 5 0.016; Fig. 3). Alpha-tocopherol serum
levels or delta alpha-tocopherol were not related to the
impairment of FMD. The number of cigarettes smoked per
day correlated with TBARS at baseline (r 5 0.49, p 5
0.025). No significant correlation was found between pack-
years and TBARS levels. The close correlation between
delta FMD and delta TBARS (r 5 20.71, p 5 0.031) also
remained following exclusion of the placebo group.
DISCUSSION
This study demonstrates a partially beneficial effect of
vitamin E supplementation on endothelium-dependent va-
sodilation in the brachial artery of male smokers. Vitamin E
supplementation for four weeks prevented the transient
further impairment of endothelium-dependent vasodilation
after acute smoking, while it showed no effect on chronic
Table 2. Oxidation Parameters and Results of Ultrasound Measurements in the Brachial Artery
Placebo (n 5 11) Vitamin E (n 5 11) p
FMD (%) baseline 6.4 6 3.8 (0.0–10.9) 5.3 6 3.8 (0.2–13.9) 0.51
after therapy 6.9 6 3.5 (2.7–13.9) 6.9 6 4.0 (0.8–12.4) 0.98
after therapy and
acute smoking
2.7 6 2.8 (0.5–9.1) 5.8 6 3.2 (0.4–11.3) 0.028
delta FMD (%) after acute smoking 20.77 6 0.31 (21.51–20.34) 20.12 6 0.37 (20.83–0.44) 0.0002
TBARS (mmol/L) baseline 0.10 6 0.03 (0.06–0.15) 0.11 6 0.04 (0.06–0.19) 0.66
after therapy 0.13 6 0.03 (0.08–0.17) 0.10 6 0.03 (0.06–0.16) 0.056
delta TBARS (%) after therapy 0.36 6 0.42 (20.13–1.08) 20.06 6 0.35 (20.62–0.48) 0.033
alpha-tocopherol (mg/ml) baseline 12.2 6 3.8 (4.5–19.6) 14.5 6 3.6 (9.6–20.7) 0.17
after therapy 13.3 6 3.8 (6.4–20.2) 23.5 6 6.6 (13.0–32.6) 0.0005
delta alpha-tocopherol (%) after therapy 0.07 6 0.24 (20.34–0.37) 0.62 6 0.27 (0.18–1.07) 0.0002
alpha-tocopherol/LDL-C baseline 10.2 6 3.4 (4.5–19.6) 10.7 6 4.3 (9.6–20.7) 0.75
(mg/100 mg% LDL) after therapy 11.0 6 2.9 (6.6–14.8) 16.7 6 6.3 (7.6–28.4) 0.018
delta alpha-tocopherol/LDL-C (%) after therapy 0.17 6 0.40 (20.44–0.96) 0.60 6 0.42 (0.08–1.35) 0.035
FMD 5 flow-mediated dilation; LDL-C 5 low-density lipoprotein; TBARS 5 thiobarbituric acid–reactive substances.
delta TBARS, delta alpha-tocopherol and delta FMD 5 percent changes after therapy and heavy smoking, respectively.
Values are mean 6 SD (range), p 5 for comparison of subjects receiving placebo and subjects receiving vitamin E (600 IU).
Figure 1. Bar graph showing FMD values of subjects receiving
placebo and of subjects receiving vitamin E (600 IU/day) at
baseline, after therapy for four weeks and after heavy smoking at
the end of the treatment period. Time factor p value 5 0.0065.
Group factor p value 5 0.5834. Interaction of the time factor and
the grouping factor: p 5 0.0318. FMD 5 flow-mediated vasodi-
lation. Open square 5 placebo; closed square 5 Vitamin E.
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endothelial dysfunction in these subjects. In addition, the
attenuation of transient endothelial dysfunction after acute
smoking correlated with an improvement of the antioxidant
status under vitamin E supplementation.
Effects of chronic smoking on endothelial dysfunction.
Endothelial dysfunction has been observed in both periph-
eral and coronary arteries of long-term smokers (1,2). The
precise mechanism of this impairment by chronic smoking
has not yet been elucidated but may be related to oxidative
stress. In support of this, cigarette smoke has been shown to
contain large amounts of free radicals such as superoxide
anion and hydroxyl radicals (11,22), agents known to
degrade endothelium derived relaxing factor and to impair
FMD (6). Superoxide anion, in turn, can rapidly react with
nitric oxide to form peroxynitrite, a molecule with high
cytotoxic potency (23,24). Moreover, it has been reported
that cigarette smokers have higher rates of in vivo and in
vitro lipid peroxidation (25). Thus, atherogenic effects of
smoking may be mediated in part by free radical damage to
lipids, in particular oxidative modification of LDL, which
promotes foam cell formation (26,27), monocyte adhesion
(28,29) and is cytotoxic to vascular cells (30).
Role of antioxidants in smokers. Epidemiologic studies
have shown that plasma levels of antioxidant nutrients, such
as vitamin C and E, are significantly lower in smokers
compared with nonsmokers (31). In the Health Profession-
als’ follow-up study, a reduction in major coronary events
among healthy male subjects taking 100 to 250 IU supple-
mentation of vitamin E per day, with little further benefit at
higher doses, was reported (8). In contrast, in a randomized
therapeutic trial among Finnish smokers, no beneficial effect
on cardiovascular events was observed for either vitamin E
or beta-carotene intake (32). However, the dose of vitamin
E applied in this study (50 mg per day) was below the
protective range suggested in the Health Professionals’
follow-up study. Therefore, a cause-and-effect relation be-
tween vitamin E intake and a reduction in cardiovascular
events has thus far been suggested only for vitamin E
supplementation in patients with angiographically proven
coronary atherosclerosis (10).
Effects of antioxidant vitamins on endothelial function in
smokers. Endothelium-dependent vasodilation in the fore-
arm circulation of chronic smokers can be improved by
acute intraarterial administration of vitamin C (11). More-
over, Motoyama et al. (12) demonstrated that an acute
impairment of FMD in the brachial artery after heavy
smoking is caused by an increase of oxidative stress within
10 min. This transient impairment of endothelial function
Figure 2. FMD values before and after heavy smoking at the end of the treatment period for subjects receiving placebo as well as for
subjects receiving vitamin E (600 IU/day). P values for the time factor 5 0.0001; p value for the group factor 5 0.0017. FMD 5
flow-mediated vasodilation.
Figure 3. Transient impairment of FMD (delta FMD) after heavy
smoking vs. improvement of the antioxidant status (delta TBARS)
under vitamin E supplementation for four weeks. FMD 5
flow-mediated dilation; TBARS 5 thiobarbituric acid-reactive
substances.
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lasts for #90 min (4) and can be attenuated by intravenous
infusion of vitamin C (12). In contrast, oral vitamin E
supplementation did not improve endothelial function in
the forearm circulation of normocholesterolemic chronic
smokers (33). Our data suggest that the oral intake of
vitamin E for four weeks is not able to reverse chronic
endothelial dysfunction of smokers but does prevent the
transient further impairment of endothelium-dependent
vasodilation in the brachial artery after acute smoking. This
acute effect is likely due to the antioxidant effect of vitamin
E which is supported by its close correlation with
1) the decrease in TBARS, reflecting attenuation of oxida-
tive stress under vitamin E supplementation and
2) the increase of alpha-tocopherol plasma levels normal-
ized to LDL-C, suggesting reduced lipid peroxidation
under therapy (19,20). Since TBARS are used to mea-
sure actual oxidative stress, it was not surprising that
TBARS levels correlated with the total number of
cigarettes smoked per day and not with the number of
pack-years.
Interestingly, no improvement of chronic endothelial
dysfunction was found, although the oxidative status was
improved. These results are in accordance with previous
observations in the forearm vasculature, in which vitamin E
supplementation failed to improve endothelium-dependent
vasodilation, although the susceptibility of LDL to oxida-
tion could be reduced (34). However, the beneficial effect of
vitamin E supplementation on the impairment of endothe-
lial function after heavy smoking reported in this study is
unlikely due to increased resistance of LDL-C to oxidation,
as this process would last longer than the time elapsed
between heavy smoking and the ultrasound examination
(20). Thus, other mechanisms must be considered, such as
the scavenging of superoxide or an improvement of the
intracellular antioxidant status due to the accumulation of
alpha-tocopherol in the vascular wall and in endothelial cells
in particular (35).
A possible explanation for the discrepancy between the
lack of effect on chronic endothelial dysfunction after
vitamin E supplementation and its beneficial effect on
transient endothelial dysfunction in our study may be the
relatively low degree of oxidative stress while subjects
refrained from smoking before the examination, compared
with the burst of oxidative stress after heavy smoking.
Recently, Heitzer et al. (33) revealed a beneficial effect of
vitamin E supplementation on chronic endothelial dysfunc-
tion selectively in hypercholesterolemic smokers which was
associated with a reduction of elevated autoantibody titers
against oxidized LDL. Alternatively, chronic endothelial
dysfunction caused by smoking may be due to other mech-
anisms not affected by the antioxidant or other properties of
vitamin E. These mechanisms may include an increase in
asymmetric dimethylarginine, an endogenous nitric oxide
synthase inhibitor (36), as well as more long-lasting endo-
thelial cell damage, due to cytotoxic intermediates (23,24).
Study limitations. A possible drawback of this study may
be that we did not measure TBARS after heavy smoking.
However, an acute increase of TBARS after heavy smoking
as well as an attenuation of this increase by an antioxidant
has been demonstrated previously (12). In this study,
TBARS levels and alpha-tocopherol serum levels normal-
ized to LDL-C were measured to estimate the attenuation
of oxidative stress under vitamin E supplementation. The
fact that TBARS levels were not significantly different in
both study groups (p 5 0.06) is most likely due to the high
SD of this parameter (19). However, differences in delta
TBARS, alpha-tocopherol/LDL-C and delta alpha-
tocopherol/LDL-C strongly suggest an improvement in the
antioxidant status of subjects taking vitamin E. Finally, we
cannot exclude that the duration of vitamin E treatment
may have been insufficient. However, long term vitamin E
supplementation for four months also failed to restore
endothelial function in long-term smokers with a lipid
profile similar to our study subjects (33).
Conclusions. This study demonstrates that oral vitamin E
supplementation can attenuate the transient impairment of
endothelial function after heavy smoking due to an im-
provement of the antioxidant status, but cannot restore
chronic endothelial dysfunction within four weeks. These
data are consistent with the concept that vitamin E may in
part be beneficial due to direct tissue effects that are different
from the prevention of the formation of oxidized LDL-C.
Reprint requests and correspondence: Dr. Thomas Neunteufl,
Department of Cardiology, University of Vienna Medical School,
Wa¨hringer Gu¨rtel 18-20, A-1090 Vienna, Austria. E-mail:
TNEUNTEUFL@pop3.kard.akh-wien.ac.at.
REFERENCES
1. Zeiher AM, Scha¨chinger V, Minners J. Long term cigarette smoking
impairs endothelium-dependent coronary arterial vasodilator function.
Circulation 1995;92:1094–100.
2. Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette
smoking is associated with dose-related and potentially reversible
impairment of endothelium-dependent dilation in healthy young
adults. Circulation 1993;88:2149–55.
3. Lekakis J, Papamichael C, Vemmos C, et al. Effect of acute cigarette
smoking on endothelium-dependent brachial artery dilation in healthy
individuals. Am J Cardiol 1997;79:529–31.
4. Lekakis J, Papamichael C, Vemmos C, et al. Endothelial dysfunction
after cigarette smoking. Insights on duration of the phenomenon and
development of tolerance (abstr). Circulation 1997;96:I–355.
5. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating
products of lipid peroxidation (F2-isoprostanes) in smokers. N Engl
J Med 1995;332:1198–203.
6. Murohara T, Kugiyama K, Ohgushi M, et al. Cigarette smoke extract
contracts isolated porcine coronary arteries by superoxide anion-
mediated degradation of EDRF. Am J Physiol 1994;266:H874–80.
7. Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of
oxidant stress in vivo in chronic cigarette smokers. Circulation 1996;
94:19–25.
8. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption
and the risk of coronary heart disease in men. N Engl J Med
1993;328:1450–6.
9. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consump-
282 Neunteufl et al. JACC Vol. 35, No. 2, 2000
Vitamin E and Endothelial Function in Smokers February 2000:277–83
tion and the risk of coronary disease in women. N Engl J Med
1993;328:1444–9.
10. Stephens NG, Parsons A, Schofield PM, et al. Randomized controlled
trial of vitamin E in patients with coronary disease: Cambridge Heart
Antioxidant Study (CHAOS). Lancet 1996;347:781–6.
11. Heitzer T, Just H, Mu¨nzel T. Antioxidant vitamin C improves
endothelial dysfunction in chronic smokers. Circulation 1996;94:6–9.
12. Motoyama T, Kawano H, Kugiyama K, et al. Endothelium-dependent
vasodilation in the brachial artery is impaired in smokers: effect of
vitamin C. Am J Physiol 1997;273:H1644–50.
13. Gilligan DM, Sack MN, Guetta V, et al. Effect of antioxidant
vitamins on low density lipoprotein oxidation and impaired
endothelium-dependent vasodilation in patients with hypercholester-
olemia. J Am Coll Cardiol 1994;24:1611–7.
14. Levine GN, Frei B, Koulouris SN, et al. Ascorbic acid reverses
endothelial vasomotor dysfunction in patients with coronary artery
disease. Circulation 1996;93:1107–13.
15. Neunteufl T, Kostner K, Katzenschlager R, et al. Additional benefit of
vitamin E supplementation to simvastatin therapy on vasoreactivity of
the brachial artery of hypercholesterolemic men. J Am Coll Cardiol
1998;32:711–6.
16. Celermajer DS, Sorensen KE, Gooch VM, et al. Noninvasive detec-
tion of endothelial dysfunction in children and adults at risk of
atherosclerosis. Lancet 1992;340:1111–5.
17. Neunteufl T, Katzenschlager R, Abela C, et al. Impairment of
endothelium-independent vasodilation in patients with hypercalcemia.
Cardiovasc Res 1998;40:396–401.
18. Rhys WAT. Simultaneous determination of serum vitamin A and E by
HPLC with fluorescence detection. J Chromatogr 1985;341:198.
19. Kostner K, Hornykewycz S, Young P, et al. Is oxidative stress causally
linked to unstable angina pectoris? A study in 100 CAD patients and
matched controls. Cardiovasc Res 1997;36:330–6.
20. Dieber-Rotheneder M, Puhl H, Waeg G, et al. Effect of oral
supplementation with alpha tocopherol on the vitamin E content of
human LDL and resistance to oxidation. J Lipid Res 1991;21:1325–32.
21. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid
peroxidation products: malonaldehyde and 4-hydroxynonenal. Meth
Enzymol 1990;186:407.
22. Benowitz N. Drug therapy: pharmacologic aspects of cigarette smok-
ing and nicotine addiction. N Engl J Med 1988;319:1318–30.
23. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced
membrane lipid peroxidation: the cytotoxic potential of superoxide and
nitric oxide. Arch Biochem Biophys 1991;288:481–7.
24. White CR, Brock TA, Chang LY, et al. Superoxide and peroxynitrite
in atherosclerosis. Proc Natl Acad Sci USA 1994;91:1044–8.
25. Miller ER, Appel LJ, Jiang L, Risby TH. Association between
cigarette smoking and lipid peroxidation in a controlled feeding study.
Circulation 1997;96:1097–101.
26. Berliner JA, Territo MC, Sevanian A, et al. Minimally modified low
density lipoprotein stimulates monocyte endothelial interactions.
J Clin Invest 1990;85:1260–6.
27. Rajavashisth TB, Andalibi A, Territo MC, et al. Induction of
endothelial cell expression of granulocyte and macrophage colony-
stimulating factors by modified low density lipoproteins. Nature
1990;344:254–7.
28. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a
chemotactic factor for human monocytes and its potential role in
atherogenesis. Proc Natl Acad Sci USA 1988;85:2805–9.
29. Frostegard J, Haegerstrand A, Gidlund M, Nilsson J. Biologically
modified LDL increases the adhesive properties of endothelial cells.
Atherosclerosis 1991;90:119–26.
30. Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein
cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res
1983;24:1070–6.
31. Schectman G, Byrd JC, Gruchow HW. The influence of smoking on
vitamin C status in adults. Am J Public Health 1989;79:158–62.
32. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study
Group. The effect of vitamin E and beta carotene on the incidence of
lung cancer and other cancers in male smokers. N Engl J Med
1994;330:1029–35.
33. Heitzer T, Herttuala SY, Wild E, et al. Effect of vitamin E on
endothelial vasodilator function in patients with hypercholesterolemia,
chronic smoking or both. J Am Coll Cardiol 1999;33:499–505.
34. Gilligan DM, Sack MN, Guetta V, et al. Effect of antioxidant
vitamins on low density lipoprotein oxidation and impaired
endothelium-dependent vasodilation in patients with hypercholester-
olemia. J Am Coll Cardiol 1994;24:1611–7.
35. Keaney JF, Jr, Guo Y, Cunningham D, et al. Vascular incorporation of
alpha-tocopherol prevents endothelial dysfunction due to oxidized
LDL by inhibiting protein kinase C stimulation. J Clin Invest
1996;98:386–94.
36. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide
synthase inhibitor. A novel marker of atherosclerosis. Circulation
1999;99:1141–6.
283JACC Vol. 35, No. 2, 2000 Neunteufl et al.
February 2000:277–83 Vitamin E and Endothelial Function in Smokers
